Abstract
Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their pharmacokinetic profile, possibly affecting treatment response. Therefore, prediction of therapy outcome based on genotypes would enable a more personalized medicine approach, providing optimal therapy for each patient. In this review, the authors will discuss the current evidence on the most important metabolizing enzymes in endocrine therapy, with a special focus on CYP2D6 and its role in tamoxifen metabolism.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Androstadienes / administration & dosage
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Aromatase Inhibitors / administration & dosage
-
Biomarkers, Pharmacological / metabolism*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Cytochrome P-450 CYP2D6 / genetics
-
Cytochrome P-450 CYP2D6 / metabolism*
-
Female
-
Humans
-
Letrozole
-
Nitriles / administration & dosage
-
Receptors, Estrogen / genetics
-
Receptors, Estrogen / metabolism
-
Tamoxifen / administration & dosage
-
Triazoles / administration & dosage
Substances
-
Androstadienes
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Biomarkers, Pharmacological
-
Nitriles
-
Receptors, Estrogen
-
Triazoles
-
Tamoxifen
-
Letrozole
-
Cytochrome P-450 CYP2D6
-
exemestane